PHARNEXT Revenue

Biotechnology Research • Suresnes, Île-de-France, France • 11-20 Employees

PHARNEXT revenue & valuation

Annual revenue	$90,592
Revenue per employee	$5,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$289,894
Total funding	$98,700,000

Key Contacts at PHARNEXT

Serguei Nabirotchkine

Co-Founder And Chief Biology Officer

Agnes Daoust

Director Clinical Operations

Daniel Cohen

Ceo

Youcef Boutalbi

Medical Affairs Director

Company overview

Headquarters	14 rue de la République, Suresnes, Île-de-France 92150, FR
Phone number	+33141092230
Website	pharnext.com
NAICS	541714
SIC	873
Keywords	Maladies Neurodégénératives, Études Cliniques, Développement De Molécules
Founded	2007
Employees	11-20
Socials

PHARNEXT Email Formats

PHARNEXT uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@pharnext.com), used 83.3% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@pharnext.com	83.3%
{first name}{last name}	johndoe@pharnext.com	16.7%

About PHARNEXT

Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with positive topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and benefits from orphan drug status in Europe and the United States. An international pivotal Phase III study of PXT3003 in CMT1A, the PREMIER trial, is currently ongoing. PXT864 has generated encouraging Phase II results in Alzheimer’s disease and will be advanced through partnerships. Both of Pharnext’s lead assets originated from the Pleotherapy™ R&D approach. Pharnext draws the attention of investors to the financial and other risk factors detailed in its financial reports. More information can be found at www.pharnext.com. Pharnext is listed on the Euronext Growth Stock Exchange in Paris.

Employees by Management Level

Total employees: 11-20

Seniority

Employees

C-Suite

Director

Entry

Employees by Department

PHARNEXT has 6 employees across 4 departments.

Departments

Number of employees

Funding Data

Explore PHARNEXT's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-07-07	14	$98,700,000

Funding Insights

$98,700,000

Total funding amount

$98,700,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

PHARNEXT is located in Suresnes, Île-de-France, FR.

You can reach PHARNEXT at +33141092230.

PHARNEXT generates an estimated annual revenue of $90,592. This revenue figure reflects the company's market position and business performance in its industry.

PHARNEXT has an estimated valuation of $289,894. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

PHARNEXT was founded in 2007, making it 19 years old. The company has established itself as a significant player in its industry over this time.

PHARNEXT has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.

PHARNEXT has raised a total of $98,700,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.